CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8,687 enrolled
Drug / intervention
Herpes Zoster Vaccine GSK1437173Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02690207
NCT02690207Phase 3Completed
CompareCT.gov

Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies

GlaxoSmithKline·interventional·Posted Feb 24, 2016·Updated Mar 4, 2021

In Brief

A Phase 3 clinical trial evaluating Herpes Zoster Vaccine GSK1437173A for Herpes Zoster. Completed, enrolled 8,687 participants across 195 sites in 18 countries.

Detailed Summary

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesAustralia, Brazil, Canada, Czechia, Estonia, Finland, France, Germany, Hong Kong, Italy, Japan, Mexico, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 24, 2016
Enrollment StartMar 16, 2016
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.4 years ago

Interventions

Herpes Zoster Vaccine GSK1437173Abiological

Intramuscular injection